![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Adherence to Prescribed Doses of ABT-450/r/Ombitasvir, Dasabuvir, and Ribavirin in the Phase 3 PEARL-II, PEARL-III, and PEARL-IV Trials
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
David Bernstein1, Rui T Marinho2, Daniel E Cohen3, Fritz Bredeek4, Ferenc Schneider5, Gunnar Norkrans6, Manuela Curescu7, Michael Bennett 8, Marina Maevskaya9, Jeff rey Fessel10, Wangang Xie3, Yan Luo3, Jeff rey V Enejosa3
1Hofstra North Shore-LIJ School of Medicine, Manhasset, New York, United States; 2Centro Hospitalar Lisboa Norte, Medical School of Lisbon, Lisbon, Portugal; 3AbbVie Inc., North Chicago, Illinois, United States; 4Metropolis Medical Group, San Francisco, California, United States; 5Markusovszky Hospital, Szombathely, Hungary;
6Sahlgrenska University Hospital, Goteborg, Sweden; 7Life Search SRL, Timisoara, Romania; 8Medical Associates Research Group, San Diego, California, United States; 9First Moscow State Medical Universita naIM Sechenov, Moscow, Russia; 10Kaiser Permanente, San Francisco, California, United States
![AASLD1.gif](../images/120114/120114-6/AASLD1.gif)
![AASLD2.gif](../images/120114/120114-6/AASLD2.gif)
![AASLD3.gif](../images/120114/120114-6/AASLD3.gif)
![AASLD4.gif](../images/120114/120114-6/AASLD4.gif)
![AASLD5.gif](../images/120114/120114-6/AASLD5.gif)
![AASLD6.gif](../images/120114/120114-6/AASLD6.gif)
![AASLD7.gif](../images/120114/120114-6/AASLD7.gif)
![AASLD8.gif](../images/120114/120114-6/AASLD8.gif)
![AASLD9.gif](../images/120114/120114-6/AASLD9.gif)
![AASLD10.gif](../images/120114/120114-6/AASLD10.gif)
![AASLD11.gif](../images/120114/120114-6/AASLD11.gif)
![AASLD12.gif](../images/120114/120114-6/AASLD12.gif)
![AASLD13.gif](../images/120114/120114-6/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|